Tianshu Liu
Postdoctoral Associate in Cell BiologyAbout
Research
Publications
2026
P 25 (MULTI) Enhancing the Therapeutic Ratio with Proton FLASH-SFRT using Bragg Peak GRID Delivery
Selvaraj B, Qi H, Zhao X, Xu L, Kang M, Zheng A, Ho M, Tsai P, Rahman R, Yu F, Zhai A, Lee N, Guha C, Liu T, Yacoub I, Chhabra A, Choi J, Simone C, Lin H, Wei S. P 25 (MULTI) Enhancing the Therapeutic Ratio with Proton FLASH-SFRT using Bragg Peak GRID Delivery. International Journal Of Particle Therapy 2026, 19: 101277. DOI: 10.1016/j.ijpt.2025.101277.Peer-Reviewed Original ResearchO 31 Interruption in ultra-high dose rate pencil beam scanning proton delivery: Dosimetric impact and clinical solutions
Qi H, Zheng A, Tsai P, Yu F, Zhai A, Kang M, Liu T, Bakst R, Tome W, Guha C, Lee N, Yacoub I, Choi J, Chhabra A, Simone C, Lin H, Wei S. O 31 Interruption in ultra-high dose rate pencil beam scanning proton delivery: Dosimetric impact and clinical solutions. International Journal Of Particle Therapy 2026, 19: 101246. DOI: 10.1016/j.ijpt.2025.101246.Peer-Reviewed Original ResearchTrastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2-Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial.
Liu T, Luo S, Yuan X, Liu D, Zhou Z, Wang X, Deng Y, Chen J, Liu M, Zhou H, Ren X, Qiu W, Cao Y, Cai S, Dong Y, Zhang Y, Wang W, Liang J, Xu P, Liu H, Zhao K, Fan Y, Dou N, Huang C, Li J. Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2-Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial. Journal Of Clinical Oncology 2026, jco2500716. PMID: 41779980, DOI: 10.1200/jco-25-00716.Peer-Reviewed Original ResearchHuman epidermal growth factor receptor 2Treatment-related adverse eventsProgression-free survivalDose-limiting toxicityGastroesophageal junction adenocarcinomaAntibody-drug conjugatesPhase I trialColorectal cancerMedian OSJunction adenocarcinomaOverall survivalI trialGastric cancerHER2-positive colorectal cancerHER2-targeting antibody-drug conjugateEpidermal growth factor receptor 2Median overall survivalAdvanced gastric cancerDose cohortsOpen-labelStandard treatmentAdverse eventsTrastuzumabReceptor 2PatientsSOX4-activated lncRNA AC004854.2 promotes colorectal cancer progression by disrupting the PUF60–FUBP1 complex and activating c-MYC transcription
Chen Y, Wang R, Zhu D, Cheng L, Zhao J, Xiguo, Liang L, Liu T. SOX4-activated lncRNA AC004854.2 promotes colorectal cancer progression by disrupting the PUF60–FUBP1 complex and activating c-MYC transcription. Genes & Diseases 2026, 102137. DOI: 10.1016/j.gendis.2026.102137.Peer-Reviewed Original ResearchC-myc transcriptionFar-upstream elementC-MycSRY-box transcription factor 4Promoter regionG1 phase cell cycle arrestC-myc promoterLevels of c-MycCell cycle arrestTranscription factor 4C-Myc inhibitorC-Myc signalingCancer cell proliferationRepressor complexTherapeutic targetInvasion in vitroColorectal cancer cell proliferationTumor growth in vivoCycle arrestColorectal cancerGrowth in vivoTranscript expressionAssociated with poor clinical prognosisEffective therapeutic targetFunctional studiesDosimetric Correlates of Acute Toxicities for Moderate Hypofractionated Whole Breast Irradiation: Implications for ASTRO Planning Guidelines
Dumane V, Runnels J, Cohen M, Fu W, Jackson A, Wang J, Yang K, Mazumdar M, Liu T, Green S. Dosimetric Correlates of Acute Toxicities for Moderate Hypofractionated Whole Breast Irradiation: Implications for ASTRO Planning Guidelines. Advances In Radiation Oncology 2026, 102031. DOI: 10.1016/j.adro.2026.102031.Peer-Reviewed Original ResearchHypofractionated whole breast irradiationWhole breast irradiationHF-WBIPrevalent side effectsBreast irradiationMoist desquamationDosimetric correlationsField-in-field plansModerate to severe painDose-volume parametersHigh dose regionAcute toxicityLogistic regression analysisASTRO guidelinesCTCAE v5.0Dose homogeneitySevere painClinical outcomesRelated toxicityGuideline updateTreatment visitsMultivariate analysisDose regionPainPatientsAssociation between cholesterol and liver injury risk in solid cancer patients treated with PD-1 inhibitors: evidence from two cohort studies
Lei J, Wang Y, Jin Z, Qin G, Liu T, Zhang N, Lv M. Association between cholesterol and liver injury risk in solid cancer patients treated with PD-1 inhibitors: evidence from two cohort studies. BMC Cancer 2026 PMID: 41761173, DOI: 10.1186/s12885-026-15801-0.Peer-Reviewed Original ResearchHepatic immune-related adverse eventsImmune-related adverse eventsLDL-C levelsCancer patients treated with PD-1 inhibitorsPatients treated with PD-1 inhibitorsPD-1 inhibitor therapyElevated LDL-C levelsPD-1 inhibitorsPD-1Inhibitor therapyValidation cohortLDL-CHDL-CBaseline levels of total cholesterolLipoprotein cholesterolDiscovery cohortTotal cholesterolBaseline LDL-C levelsMultivariate Cox regression analysisBaseline serum lipidsRestricted cubic spline modelsBaseline levelsHigh-density lipoprotein cholesterolLow-density lipoprotein cholesterolBaseline lipid levelsErgostane steroid, as one of the major contributor to cranberry derived extracellular vesicle nanoparticles, restores ovarian function of murine premature ovarian failure
Cui Z, Lai Y, Liu T, Yang L, Huang Y. Ergostane steroid, as one of the major contributor to cranberry derived extracellular vesicle nanoparticles, restores ovarian function of murine premature ovarian failure. Journal Of Nanobiotechnology 2026, 24: 303. PMID: 41742181, DOI: 10.1186/s12951-026-04153-3.Peer-Reviewed Original ResearchPremature ovarian failureHigh-throughput metabolomics analysisOvarian granulosa cellsOvarian functionOvarian failureTherapeutic effectGranulosa cellsMetabolomic analysisOral deliveryResultsOral administrationAbnormal expressionModel miceVesicle nanoparticlesMurine ovarian tissueProportion of atretic folliclesSex hormone levelsGranulosa cell morphologyImmunohistochemical staining methodBlood lipid disordersCellular senescence markersConventional H&EOvarian insufficiencyWestern blot analysisOvarian tissueAtretic folliclesReal-World Evaluation of the Efficacy of Third-Line Treatment Regimens for Advanced Gastric Cancer: A Single-Center Retrospective Study
Zhou X, Yu S, Zhu C, Liu T. Real-World Evaluation of the Efficacy of Third-Line Treatment Regimens for Advanced Gastric Cancer: A Single-Center Retrospective Study. British Journal Of Hospital Medicine 2026, 87: 50918. PMID: 41762081, DOI: 10.31083/bjhm50918.Peer-Reviewed Original ResearchConceptsThird-line treatment regimensAdvanced gastric cancerMedian survival timeThird-line treatmentLonger median survival timeChemotherapy-alone groupPrognostic factorsTreatment regimensAdverse eventsGastric cancerTherapy groupOptimal regimenHigher incidenceRetrospective studyPrognostic factors of patientsTreatment-related adverse eventsHistory of gastric surgerySingle-center retrospective studyCox proportional hazards regression analysisIncidence of adverse eventsKaplan-Meier survival curvesHigher incidence of adverse eventsProportional hazards regression analysisThird-line chemotherapyThird-line therapyAnlotinib in combination with trifluridine-tipiracil in patients with refractory metastatic colorectal cancers: a phase II, single arm study
Liu Q, Zhang C, Liu M, Peng K, Xu X, Yu Y, Liu T. Anlotinib in combination with trifluridine-tipiracil in patients with refractory metastatic colorectal cancers: a phase II, single arm study. The Oncologist 2026, 31: oyag019. PMID: 41719193, PMCID: PMC12958117, DOI: 10.1093/oncolo/oyag019.Peer-Reviewed Original ResearchManagement of metastatic colorectal cancerProgression-free survivalDisease control rateTreatment-emergent adverse eventsCombination of anlotinibMetastatic colorectal cancerPhase II studyStable diseasePartial responseOverall survivalII studyManagement of metastatic colorectal cancer patientsColorectal cancerSingle-arm phase II studyThird-line treatment strategiesRefractory metastatic colorectal cancerLate-line settingsEmergent adverse eventsStandard treatment regimensSingle arm studyKaplan-Meier estimatesTrifluridine-tipiracilOpen-labelMedian agePrimary endpointUpdated survival analysis of cadonilimab (AK104) monotherapy in recurrent or metastatic cervical cancer: focus on complete responders
Zheng Z, Lou H, Ji J, Li Y, Li Y, Xu N, Feng M, Huang Y, Lou G, Wang J, An R, Li C, Zhou Q, Huang X, Zhao E, Liu T, Lu Q, Li W, Xia M, Wu X. Updated survival analysis of cadonilimab (AK104) monotherapy in recurrent or metastatic cervical cancer: focus on complete responders. International Journal Of Gynecological Cancer 2026, 36: 104417. DOI: 10.1016/j.ijgc.2025.104417.Peer-Reviewed Original Research